ImpriMed, a Mountain View, CA-based precision medicine startup focused on leveraging artificial intelligence to improve cancer treatment, raised $23M in Series A funding.
The round was led by SBVA. HRZ Han River Partners, SK Telecom, KDB Silicon Valley, Ignite Innovation Fund, Samyang Chemical Group, Murex Partners, and Byucksan also participated.
The company intends to use the funds to expand its drug response prediction technology beyond veterinary medicine into human oncology, increase headcount, and broaden its business development and research and development pipeline.
Co-founded in 2017 by Sungwon Lim, CEO, and Jamin Koo, CTO—both distinguished alumni of Stanford University and KAIST (The Korea Advanced Institute of Science and Technology), ImpriMed is a precision medicine startup for cancer treatment with artificial intelligence. Its drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the company’s technology has been deployed across more than 40 U.S. states, and 15,000+ canine and feline blood cancer tests have been performed as of 2023. ImpriMed is now poised to extend its AI-driven approach to human healthcare.
FinSMEs
19/12/2023